Literature DB >> 19699552

Pseudomonas aeruginosa: a formidable and ever-present adversary.

K G Kerr1, A M Snelling.   

Abstract

Pseudomonas aeruginosa is a versatile pathogen associated with a broad spectrum of infections in humans. In healthcare settings the bacterium is an important cause of infection in vulnerable individuals including those with burns or neutropenia or receiving intensive care. In these groups morbidity and mortality attributable to P. aeruginosa infection can be high. Management of infections is difficult as P. aeruginosa is inherently resistant to many antimicrobials. Furthermore, treatment is being rendered increasingly problematic due to the emergence and spread of resistance to the few agents that remain as therapeutic options. A notable recent development is the acquisition of carbapenemases by some strains of P. aeruginosa. Given these challenges, it would seem reasonable to identify strategies that would prevent acquisition of the bacterium by hospitalised patients. Environmental reservoirs of P. aeruginosa are readily identifiable, and there are numerous reports of outbreaks that have been attributed to an environmental source; however, the role of such sources in sporadic pseudomonal infection is less well understood. Nevertheless there is emerging evidence from prospective studies to suggest that environmental sources, especially water, may have significance in the epidemiology of sporadic P. aeruginosa infections in hospital settings, including intensive care units. A better understanding of the role of environmental reservoirs in pseudomonal infection will permit the development of new strategies and refinement of existing approaches to interrupt transmission from these sources to patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699552     DOI: 10.1016/j.jhin.2009.04.020

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  148 in total

1.  IMP-29, a novel IMP-type metallo-β-lactamase in Pseudomonas aeruginosa.

Authors:  Katy Jeannot; Laurent Poirel; Marjorie Robert-Nicoud; Pascal Cholley; Patrice Nordmann; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 2.  Copper in microbial pathogenesis: meddling with the metal.

Authors:  Marie I Samanovic; Chen Ding; Dennis J Thiele; K Heran Darwin
Journal:  Cell Host Microbe       Date:  2012-02-16       Impact factor: 21.023

3.  Multidrug therapy and evolution of antibiotic resistance: when order matters.

Authors:  Gabriel G Perron; Sergey Kryazhimskiy; Daniel P Rice; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-22       Impact factor: 4.792

4.  Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.

Authors:  Veerle Liebens; Valerie Defraine; Wouter Knapen; Toon Swings; Serge Beullens; Romu Corbau; Arnaud Marchand; Patrick Chaltin; Maarten Fauvart; Jan Michiels
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Time series analysis as a tool to predict the impact of antimicrobial restriction in antibiotic stewardship programs using the example of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Matthias Willmann; Matthias Marschal; Florian Hölzl; Klaus Schröppel; Ingo B Autenrieth; Silke Peter
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

6.  A Novel RNase 3/ECP Peptide for Pseudomonas aeruginosa Biofilm Eradication That Combines Antimicrobial, Lipopolysaccharide Binding, and Cell-Agglutinating Activities.

Authors:  David Pulido; Guillem Prats-Ejarque; Clara Villalba; Marcel Albacar; Juan J González-López; Marc Torrent; Mohammed Moussaoui; Ester Boix
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 7.  Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis.

Authors:  Elio Rossi; Ruggero La Rosa; Jennifer A Bartell; Rasmus L Marvig; Janus A J Haagensen; Lea M Sommer; Søren Molin; Helle Krogh Johansen
Journal:  Nat Rev Microbiol       Date:  2020-11-19       Impact factor: 60.633

8.  Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility.

Authors:  C Slekovec; J Robert; D Trystram; J M Delarbre; A Merens; N van der Mee-Marquet; C de Gialluly; Y Costa; J Caillon; D Hocquet; X Bertrand
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-07       Impact factor: 3.267

9.  Epoxide-mediated CifR repression of cif gene expression utilizes two binding sites in Pseudomonas aeruginosa.

Authors:  Alicia E Ballok; Christopher D Bahl; Emily L Dolben; Allia K Lindsay; Jessica D St Laurent; Deborah A Hogan; Dean R Madden; George A O'Toole
Journal:  J Bacteriol       Date:  2012-07-27       Impact factor: 3.490

10.  Role of Pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics.

Authors:  Hansi Kumari; Deepak Balasubramanian; Diansy Zincke; Kalai Mathee
Journal:  J Med Microbiol       Date:  2014-01-25       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.